Skip to main content

Medical benefit pharmaceutical policies for providers

See the latest updates to our medical benefit pharmaceutical policies. 

Choose a letter to view policies by first letter:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

D

MBP 46.0 Dacogen (decitabine)
Dacogen (decitabine) is an antineoplastic analog of 2-deoxycytidine; approved by the FDA for treatment of myelodysplastic syndrome.
Reviewed 8/26/20

MBP 121.0 Dalvance (dalbavancin)
Dalvance (dalbavancin), a semisynthetic lipoglycopeptide, interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, thus preventing cross-linking.
Reviewed 8/26/20

MBP 227.0 Danyelza (naxitamab-gqgk)
Danyelza (naxitamab-gqgk) is an anti-GD2 monoclonal antibody that binds to the glycolipid disialoganglioside (GD2), which is highly expressed in neuroblastoma, and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. By binding to cell surface GD2, naxitamab induces cell lysis (of GD2-expressing cells) through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
New Policy 2/26/21

MBP 139.0 Darzalex (daratumumab)
Darzalex (daratumumab) is an IgG1Κ human monoclonal antibody directed against CD38. Darzalex is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
Revised 10/22/20

MBP 230.0 Darzalex Faspro (daratumumab-hyaluronidase)
Darzalex Faspro (daratumumab/hyaluronidase) is an Anti-CD38 monoclonal antibody combination therapy. Daratumumab is an IgG1κ human monoclonal antibody directed against CD38. CD38 is a cell surface glycoprotein which is highly expressed on myeloma cells. By binding to CD38, daratumumab inhibits the growth of CD38-expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity, antibody dependent cell mediated cytotoxicity, and antibody dependent cellular phagocytosis. Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan. At the recommended dose, hyaluronidase acts locally and the effects are reversible; permeability of subcutaneous tissue is restored within 24 to 48 hours.
New Policy 4/29/21

Related information

Learn more about Geisinger Health Plan.

Prior authorizations

Log in to NaviNet to access and view prior authorization information.

Clinical guidelines

Clinical guidelines offer providers consistent and appropriate guidance for diagnosis and treatment of specific conditions or diseases.

Terms and conditions

View GHP’s terms and conditions.

Questions? Contact us

If you have questions or need more information, contact Geisinger Health Plan.